Biohaven Ltd. (BHVN) |
| 10.97 -0.87 (-7.35%) 01-13 16:00 |
| Open: | 12.01 |
| High: | 12.24 |
| Low: | 10.545 |
| Volume: | 3,413,182 |
| Market Cap: | 1,161(M) |
| PE Ratio: | -1.46 |
| Exchange: | New York Stock Exchange |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.87 |
| Resistance 1: | 11.51 |
| Pivot price: | 11.02 |
| Support 1: | 9.32 |
| Support 2: | 7.75 |
| 52w High: | 44.28 |
| 52w Low: | 7.48 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Financials
| EPS | -7.520 |
| Book Value | -0.160 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -106.3 |
| Return on Equity (ttm) | -522.1 |
Company news
Tue, 13 Jan 2026
Biohaven (BHVN) Is Up 19.2% After Early Success With Selective Antibody Degraders In Kidney, Thyroid Diseases - simplywall.st
Mon, 12 Jan 2026
Biohaven highlights degrader platforms in new investor presentation - TipRanks
Mon, 12 Jan 2026
Biohaven Ltd Announces Investor Presentation on January 12, 2026 - TradingView — Track All Markets
Mon, 12 Jan 2026
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Mon, 12 Jan 2026
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PR Newswire
Tue, 06 Jan 2026
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 96% Upside in the Biotech Sector - DirectorsTalk Interviews
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
